Related Experiment Video
Updated: Oct 17, 2025

Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization
Published on: August 11, 2023
Pediatric choroidal neovascularization: Etiology and treatment outcomes with anti-vascular endothelial growth factors
Ratnesh Ranjan1, Romit Salian1, Shishir Verghese1
1Department of Retina and Vitreous services, Aravind Eye Hospital, Coimbatore, India.
Insights
Intravitreal anti-vascular endothelial growth factor (VEGF) injections effectively treat choroidal neovascularization (CNV) in children. This therapy led to significant visual acuity improvement and reduced macular thickness in pediatric patients.
Area of Science:
- Ophthalmology
- Retinal Diseases
- Pediatric Medicine
Background:
- Choroidal neovascularization (CNV) can impact vision in pediatric patients.
- Treatment options for pediatric CNV require evaluation for efficacy and safety.
Purpose of the Study:
- To determine the etiology and treatment outcomes of pediatric choroidal neovascularization (CNV).
- To assess the effectiveness of intravitreal anti-vascular endothelial growth factor (VEGF) agents in treating pediatric CNV.
Main Methods:
- Retrospective, single-center interventional case series.
- Treatment involved intravitreal injections of anti-VEGF agents in 26 eyes of 23 pediatric patients.
- Data collected included etiology, visual acuity, and macular thickness.
Main Results:
- Inflammatory CNV was the most common cause in the pediatric cohort.
- Intravitreal anti-VEGF therapy resulted in significant improvement in best-corrected visual acuity (BCVA) (logMAR 0.8 to 0.4, p < 0.0001).
- Mean central macular thickness (CMT) significantly decreased (367.6 µm to 242.5 µm, p < 0.0001) with a mean of two injections per eye.
Conclusions:
- Intravitreal anti-VEGF therapy is an effective treatment for pediatric choroidal neovascularization.
- The treatment demonstrated positive outcomes in visual acuity and macular structure in children.
Purpose:
To describe the etiology and treatment outcomes of choroidal neovascularization (CNV) in a pediatric population with intravitreal anti-vascular endothelial growth factors (VEGF).
Methods:
Retrospective single center interventional case series. A total of 26 eyes of 23 consecutive pediatric patients with CNV of various etiologies were treated with intravitreal injection of anti-VEGF agents.
Results:
There were 15 males (65.2%) and eight females (34.8%), diagnosed with CNV during the study period. The mean age at presentation with CNV was 11.7 ± 3.3 years, (range 4-16 years) and the mean follow was 28.1 ± 18 months, (range 8-72 months). Inflammatory CNV was the most common etiology. The mean best corrected visual acuity (BCVA) and mean central macular thickness (CMT) at presentation, were logMAR 0.8 ± 0.3 and 367.6 ± 134.8 µm respectively. At the final visit, CNV in all eyes remained regressed with significant improvement in mean BCVA to logMAR 0.4 ± 0.4 (p < 0.0001) and mean CMT to 242.5 ± 82.4 µm (p < 0.0001). A mean of two intravitreal injections per eye was required for CNV regression.
Conclusion:
Intravitreal anti-VEGF therapy for pediatric CNV is an effective treatment in majority of affected eyes.
Related Concept Videos
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Angle Closure Glaucoma: Treatment
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Regulation of Angiogenesis and Blood Supply
Esophageal Varices-II: Clinical Features and Management
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
Glaucoma: Overview

